Eurofins acquires of Boston Heart Diagnostics Corporation
Eurofins Scientific announces the successful closing of the transaction to acquire Boston Heart Diagnostics Corp. (Boston Heart) following review and approval from relevant regulatory bodies.
Eurofins signed an agreement to acquire Boston Heart for an initial cash amount US$140 million, plus an earn-out payment that is expected to be in excess of US$60 million upon achievement of certain milestones. Boston Heart utilizes a suite of proprietary diagnostics in combination with additional clinical and genetic tests, extensive cardio-informatics capabilities, and ancillary patient engagement services to provide an advanced diagnostics platform to help identify and reduce the risk of cardiovascular disease, diabetes, and other chronic conditions. The company is projected to achieve around $95 million of revenues in 2014, representing a CAGR of over 75% since 2011.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.